Effects of HM30181, a P-glycoprotein inhibitor, on the pharmacokinetics and pharmacodynamics of loperamide in healthy volunteers

British Journal of Clinical Pharmacology

Volumn 78, Issue 3, 2014, Pages 556-564

  Kim, Tae Eun ^a,d   Lee, Howard ^b   Lim, Kyoung Soo ^a   Lee, Seunghwan ^a   Yoon, Seo Hyun ^a   Park, Kyung Mi ^c   Han, Hyesun ^c   Shin, Sang Goo ^a   Jang, In Jin ^a   Yu, Kyung Sang ^a   Cho, Joo Youn ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Hospital   (South Korea)

^c Hanmi Pharmaceutical Co Ltd   (South Korea)

^d Konkuk University Hospital   (South Korea)

Author keywords

HM30181; loperamide; P glycoprotein inhibitor; pharmacodynamics; pharmacokinetics

Indexed keywords

GLYCOPROTEIN P INHIBITOR; HM 30181; LOPERAMIDE; MULTIDRUG RESISTANCE PROTEIN; N [2 [2 [4 (2 (6,7 DIMETHOXY 3,4 DIHYDROISOQUINOLIN 2(1H) YL)ETHYL)PHENYL] 2H TETRAZOL 5 YL] 4,5 DIMETHOXYPHENYL] 4 OXO 4H CHROMENE 2 CARBOXAMIDE; QUINIDINE; UNCLASSIFIED DRUG; 4-OXO-4H-CHROMENE-2-CARBOXYLIC ACID (2-(2-(4-(2-(6,7-DIMETHOXY-3,4-DIHYDRO-1H-ISOQUINOLIN-2-YL)-ETHYL)-PHENYL)-2H-TETRAZOL-5-YL)-4,5-DIMETHOXYPHENYL)AMIDE; ANTIDIARRHEAL AGENT; BENZOPYRAN DERIVATIVE; ISOQUINOLINE DERIVATIVE; TETRAZOLE DERIVATIVE;

ADULT; ALERTNESS; AREA UNDER THE CURVE; ARTICLE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EXPOSURE; ENDOTHELIUM; HUMAN; HUMAN EXPERIMENT; INTESTINAL ENDOTHELIUM; INTESTINE; MALE; NORMAL HUMAN; OXYGEN SATURATION; PRIORITY JOURNAL; PUPIL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; ANTAGONISTS AND INHIBITORS; BIOAVAILABILITY; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECTS; DRUG INTERACTION; INTESTINE MUCOSA; METABOLISM; MIDDLE AGED; YOUNG ADULT;

ADULT; ANTIDIARRHEALS; AREA UNDER CURVE; BENZOPYRANS; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HUMANS; INTESTINAL MUCOSA; ISOQUINOLINES; LOPERAMIDE; MALE; MIDDLE AGED; P-GLYCOPROTEIN; PUPIL; QUINIDINE; TETRAZOLES; YOUNG ADULT;

EID: 84906486965     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12368     Document Type: Article

References (28)

1. Marzolini C, Kim RB,. Placental transfer of antiretroviral drugs. Clin Pharmacol Ther 2005; 78: 118-122. (Pubitemid 41112279)
2. Varma MV, Ashokraj Y, Dey CS, Panchagnula R,. P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement. Pharmacol Res 2003; 48: 347-359. (Pubitemid 36945333)
3. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC,. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A 1987; 84: 7735-7738.
4. Yang K, Wu J, Li X,. Recent advances in the research of P-glycoprotein inhibitors. Biosci Trends 2008; 2: 137-146.
5. Thomas H, Coley HM,. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting P-glycoprotein. Cancer Control 2003; 10: 159-165. (Pubitemid 36437822)
6. Krishna R, Mayer LD,. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 2000; 11: 265-283.
7. Kwak JO, Lee SH, Lee GS, Kim MS, Ahn YG, Lee JH, Kim SW, Kim KH, Lee MG,. Selective inhibition of MDR1 (ABCB1) by HM30181 increases oral bioavailability and therapeutic efficacy of paclitaxel. Eur J Pharmacol 2010; 627: 92-98.
8. Heykants J, Michiels M, Knaeps A, Brugmans J,. Loperamide (R 18 553), a novel type of antidiarrheal agent. Part 5: the pharmacokinetics of loperamide in rats and man. Arzneimittelforschung 1974; 24: 1649-1653.
9. Schinkel AH, Wagenaar E, Mol CA, van Deemter L,. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 1996; 97: 2517-2524. (Pubitemid 26187339)
10. Baker DE,. Loperamide: a pharmacological review. Rev Gastroenterol Disord 2007; 7 (Suppl. 3): S11-18.
11. Kim TE, Gu N, Yoon SH, Cho JY, Park KM, Shin SG, Jang IJ, Yu KS,. Tolerability and pharmacokinetics of a new P-glycoprotein inhibitor, HM30181, in healthy Korean male volunteers: single- and multiple-dose randomized, placebo-controlled studies. Clin Ther 2012; 34: 482-494.
12. Killinger JM, Weintraub HS, Fuller BL,. Human pharmacokinetics and comparative bioavailability of loperamide hydrochloride. J Clin Pharmacol 1979; 19: 211-218. (Pubitemid 9172217)
13. Sadeque AJ, Wandel C, He H, Shah S, Wood AJ,. Increased drug delivery to the brain by P-glycoprotein inhibition. Clin Pharmacol Ther 2000; 68: 231-237.
14. Kharasch ED, Hoffer C, Whittington D, Sheffels P,. Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine. Clin Pharmacol Ther 2003; 74: 543-554. (Pubitemid 37521998)
15. Kharasch ED, Hoffer C, Whittington D,. The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone. Br J Clin Pharmacol 2004; 57: 600-610. (Pubitemid 38582180)
16. Skarke C, Jarrar M, Erb K, Schmidt H, Geisslinger G, Lotsch J,. Respiratory and miotic effects of morphine in healthy volunteers when P-glycoprotein is blocked by quinidine. Clin Pharmacol Ther 2003; 74: 303-311. (Pubitemid 37222851)
17. Yamamoto Y, Inoue Y, Matsuda K, Takahashi Y, Kagawa Y,. Influence of concomitant antiepileptic drugs on plasma lamotrigine concentration in adult Japanese epilepsy patients. Biol Pharm Bull 2012; 35: 487-493.
18. Skarke C, Jarrar M, Schmidt H, Kauert G, Langer M, Geisslinger G, Lotsch J,. Effects of ABCB1 (multidrug resistance transporter) gene mutations on disposition and central nervous effects of loperamide in healthy volunteers. Pharmacogenetics 2003; 13: 651-660. (Pubitemid 38316509)
19. Tayrouz Y, Ganssmann B, Ding R, Klingmann A, Aderjan R, Burhenne J, Haefeli WE, Mikus G,. Ritonavir increases loperamide plasma concentrations without evidence for P-glycoprotein involvement. Clin Pharmacol Ther 2001; 70: 405-414. (Pubitemid 33135319)
20. Paek IB, Kim SY, Kim MS, Kim J, Lee G, Lee HS,. Characterization of human liver cytochrome P-450 enzymes involved in the O-demethylation of a new P-glycoprotein inhibitor HM-30181. J Toxicol Environ Health A 2007; 70: 1356-1364. (Pubitemid 47124004)
21. Kurnik D, Sofowora GG, Donahue JP, Nair UB, Wilkinson GR, Wood AJ, Muszkat M,. Tariquidar, a selective P-glycoprotein inhibitor, does not potentiate loperamide's opioid brain effects in humans despite full inhibition of lymphocyte P-glycoprotein. Anesthesiology 2008; 109: 1092-1099.
22. Choo EF, Kurnik D, Muszkat M, Ohkubo T, Shay SD, Higginbotham JN, Glaeser H, Kim RB, Wood AJ, Wilkinson GR,. Differential in vivo sensitivity to inhibition of P-glycoprotein located in lymphocytes, testes, and the blood-brain barrier. J Pharmacol Exp Ther 2006; 317: 1012-1018. (Pubitemid 43764103)
23. Bauer F, Wanek T, Mairinger S, Stanek J, Sauberer M, Kuntner C, Parveen Z, Chiba P, Müller M, Langer O, Erker T,. Interaction of HM30181 with P-glycoprotein at the murine blood-brain barrier assessed with positron emission tomography. Eur J Pharmacol 2012; 696: 18-27.
24. Cha YJ, Lee H, Gu N, Kim TE, Lim KS, Yoon SH, Chung JY, Jang IJ, Shin SG, Yu KS, Cho JY,. Sustained increase in the oral bioavailability of loperamide after a single oral dose of HM30181, a P-glycoprotein inhibitor, in healthy male participants. Basic Clin Pharmacol Toxicol 2013; 113: 419-424.
25. Sinex JE,. Pulse oximetry: principles and limitations. Am J Emerg Med 1999; 17: 59-67.
26. Ong CE, Coulter S, Birkett DJ, Bhasker CR, Miners JO,. The xenobiotic inhibitor profile of cytochrome P4502C8. Br J Clin Pharmacol 2000; 50: 573-580. (Pubitemid 32010017)
27. Walsky RL, Gaman EA, Obach RS,. Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol 2005; 45: 68-78.
28. Darby RA, Callaghan R, McMahon RM,. P-glycoprotein inhibition: the past, the present and the future. Curr Drug Metab 2011; 12: 722-731.